白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2010年
1期
61-64
,共4页
伊马替尼%血药浓度%意义
伊馬替尼%血藥濃度%意義
이마체니%혈약농도%의의
Imatinib%Concentration%Significance
伊马替尼已作为慢性粒细胞白血病(CML)的一线治疗药物,疗效令人鼓舞.伊马替尼的血药浓度与CML患者的生存期及缓解率相关.其血浆浓度主要受α1-酸性糖蛋白(AGP)及改变细胞色素P450(CYP3A4)酶活性的影响.监测伊马替尼血药浓度有助于指导CML的临床治疗.
伊馬替尼已作為慢性粒細胞白血病(CML)的一線治療藥物,療效令人鼓舞.伊馬替尼的血藥濃度與CML患者的生存期及緩解率相關.其血漿濃度主要受α1-痠性糖蛋白(AGP)及改變細胞色素P450(CYP3A4)酶活性的影響.鑑測伊馬替尼血藥濃度有助于指導CML的臨床治療.
이마체니이작위만성립세포백혈병(CML)적일선치료약물,료효령인고무.이마체니적혈약농도여CML환자적생존기급완해솔상관.기혈장농도주요수α1-산성당단백(AGP)급개변세포색소P450(CYP3A4)매활성적영향.감측이마체니혈약농도유조우지도CML적림상치료.
As the first line of therapy for chronic myeloid leukemia, the outcome of imatinib is encouraging. The plasma concentration of imatinib is correlated with remission rate and survival, and affected by α1 acid glycoprotein(AGP) and those drugs which will change the activities of cytochrome P450(CYP3A4). It is conductive for the treatment of CML by monitoring the plasma concentration of imatinib.
